Status:
COMPLETED
Study of Oglemilast for the Treatment of Asthma
Lead Sponsor:
Forest Laboratories
Conditions:
Asthma
Eligibility:
All Genders
18-50 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether oglemilast is safe and effective in the treatment of allergen-induced asthma.
Eligibility Criteria
Inclusion
- Mild atopic asthma
- Hyperreactivity to methacholine
- Exhibit positive response to standard allergen skin prick test
Exclusion
- Pulmonary disease other than asthma
- Asthma exacerbation within 4 weeks
- History of substance abuse
- Active cardiac disease
Key Trial Info
Start Date :
May 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT00322686
Start Date
May 1 2006
Last Update
March 20 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Forest Investigative Site
Los Angeles, California, United States, 90025